EFFECTS OF ASPIRIN ON CARDIOVASCULAR EVENTS AND BLEEDING IN THE HEALTHY ELDERLY

Aspirin is a deep-rooted therapy considered cardiovascular events’ secondary prevention. Therefore, Aspirin role in cardiovascular disease’ primary preclusion is blurred, specifically in older persons, as they have amplified risk. This research is based on the enrolled community-dwelling women and men, from 2010 to 2014 in the United States of America and Australia who were seventy years old (or ≥ 65 years of age) with no cardiovascular dementia, disability or disease. We assure that participants were randomly dispensed to take 100 mg of aspirin (enteric-coated) or placebo. The main endpoint was a compound of dementia, persistent disability or death; these endpoint results are documented accordingly. A secondary endpoint consists of core hemorrhage and fatal coronary heart disease (commonly known as cardiovascular disease, nonfatal or fatal stroke, nonfatal myocardial infarction, stroke or heart failure hospitalization). The trial was enrolled with 19114 patients of whom 9525 were allocated to obtain aspirin and 9589 to obtain placebo. After a follow up of 4.7 years’ median, the cardiovascular disease rate was 10.7 events per one thousand people per year in the group of aspirin and 11.3 events per one thousand persons per year in the group of placebo (with hazard ratio, 0.95; CI confidence interval 95%, 0.83 to 1.08). Major hemorrhage rate was 8.6 events per one thousand persons and 6.2 events per one thousand persons per year (with the hazard ratio, 1.38; 95% confidence interval, 1.18 to 1.62; P = 0.001). Low-dose aspirin use as a major strategy of prevention in older adults may result in an important high risk of major hemorrhage than placebo. Keywords: Cardiovascular events; Aspirin Effects; Elderly adult